Blood cancers, Chronic leukaemia, Chronic lymphocytic leukaemia (CLL), High grade lymphoma, Low grade lymphoma, Lymphoma, Non-Hodgkin lymphoma (NHL)
Open
Phase 1/2
This trial is looking at a drug called NVG-222 for people with lymphoma or leukaemia that has come back after treatment or got worse during treatment.
Lymphoma or leukaemia that has come back after treatment is called relapsed. If it got worse during treatment it is called refractory.
Cancer Research UK supports this trial.
Recruitment start: 17 December 2025
Recruitment end: 31 October 2030
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr William Townsend
Cancer Research UK (Centre for Drug Development)
NovalGen
This is Cancer Research UK trial number CRUKD/24/003.
Last reviewed: 04 Feb 2026
CRUK internal database number: 20104
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
